CNS Pharmaceuticals, Inc. (CNSP): who owns it and who trades it
As of Nov 16, 2026, CNSP insiders reported 2 purchases worth $44K in the last 12 months. The largest buyer was Faith L. Charles (Director), with $34K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling CNS Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, CNSP insiders reported $44K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Michal Fisher | Director | Purchase | 2,000 | $5.00 | $10K | Form 4 |
| May 18, 2026 | Faith L. Charles | Director | Purchase | 7,100 | $4.79 | $34K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Faith L. Charles | Director | $34K | – | May 18, 2026 |
| Michal Fisher | Director | $10K | – | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CNSP short interest
Low short interest. 0.1% of CNSP shares are sold short: about 1 share in 892. Over the last 12 reports the number of shares short went down 95%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1,638 CNSP shares were sold short, 0.1% of the shares outstanding, up 26.0% from the report before. At the average daily volume of 23,863 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1,638 | 0.11% | +26% | 23,863 | 1.0 |
| Oct 15, 2026 | 1,300 | 0.09% | +45% | 4,301 | 1.0 |
| Sep 30, 2026 | 898 | 0.06% | -70% | 3,007 | 1.0 |
| Sep 15, 2026 | 2,969 | 0.20% | +35% | 6,400 | 1.0 |
| Aug 31, 2026 | 2,193 | 0.15% | -83% | 10,393 | 1.0 |
| Aug 14, 2026 | 12,595 | 0.86% | +11% | 4,427 | 2.9 |
| Jul 31, 2026 | 11,374 | 1.40% | -28% | 9,344 | 1.2 |
| Jul 15, 2026 | 15,780 | 1.94% | -57% | 9,462 | 1.7 |
| Jun 30, 2026 | 36,287 | 4.47% | -6% | 13,264 | 2.7 |
| Jun 15, 2026 | 38,686 | 4.77% | -20% | 21,160 | 1.8 |
| May 29, 2026 | 48,551 | 5.98% | +59% | 128,880 | 1.0 |
| May 15, 2026 | 30,584 | 3.77% | -22% | 7.48M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
CNS Pharmaceuticals company events
CNS Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Oct 2, 2026.
- Oct 2, 2026LeadershipAs reported below under Item 5.07 of this Current Report, CNS Pharmaceuticals, Inc. held its scheduled 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan including an increase in the number of shares of common stock, par… Filing
- Jul 2, 2026AnnouncementShared information with investors. Filing
- May 4, 2026LeadershipJerzy (George) Gumulka resigned as a member of the Company’s Board of Directors . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Filing
- Mar 11, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026LeadershipCNS Pharmaceuticals, Inc. entered into an employment agreement with Lynne Kelley to serve as the Company’s Chief Medical Officer effective March 2, 2026. Filing
- Feb 17, 2026LeadershipCNS Pharmaceuticals, Inc. entered into an employment agreement with Steve O’Loughlin to serve as the Company’s Chief Financial Officer effective March 2, 2026. Filing
- Dec 17, 2025LeadershipCNS Pharmaceuticals, Inc. entered into an employment agreement with Rami Levin to serve as the Company’s Chief Executive Officer and President effective January 1, 2026. Filing
- Nov 21, 2025LeadershipAs reported below under Item 5.07 of this Current Report, CNS Pharmaceuticals, Inc. held its scheduled 2025 Annual Meeting of Stockholders at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan including an increase in the number of shares of common stock, par… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
CNS Pharmaceuticals financials
Famous investors that hold CNSP
1 of the 50 well-known investors we track reported holding CNSP in their latest 13F filing. The largest position is Ken Griffin's, worth $104K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 19,695 | $104K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about CNS Pharmaceuticals, Inc. (CNSP) stock
Are CNSP insiders buying or selling?
In the last 12 months, CNSP insiders reported 2 open-market purchases worth $44K and no sales. The latest trade was on May 18, 2026. See every trade.
What is the short interest in CNSP?
As of Oct 30, 2026, 1,638 CNSP shares were sold short, 0.1% of the shares outstanding, up 26.0% from the report before. At the average daily volume of 23,863 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold CNSP?
1 of the 50 well-known investors we track reported CNSP in their latest 13F filing, including Ken Griffin. The largest position is worth $104K. See all holders.
Executive pay
CNS Pharmaceuticals's chief executive was paid a total of $1.2M for the year ended Dec 31, 2025, up 6% from $1.1M the year before. In the last 12 months, CNS Pharmaceuticals's executives and directors bought $44K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.